Lynparza is owned by Astrazeneca.

Lynparza contains Olaparib.

Lynparza has a total of 12 drug patents out of which 4 drug patents have expired.

Expired drug patents of Lynparza are:

• US8912187
• US9566276
• US9169235
• US7151102

Lynparza was authorised for market use on 17 August, 2017.

Lynparza is available in capsule;oral, tablet;oral dosage forms.

Lynparza can be used as maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen, adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, treatment of brca mutated ovarian cancer using parp inhibitor, treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone, maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability.

Drug patent challenges can be filed against Lynparza from 19 December, 2018.

The generics of Lynparza are possible to be released after 04 August, 2031.